Mosunetuzumab for Aggressive B-Cell Lymphoma

Recruiting at 1 trial location

Overseen By Armin Ghobadi, M.D.

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Washington University School of Medicine

Must not be taking: Immunosuppressants, Live vaccines

Disqualifiers: Chemotherapy-resistant lymphoma, CNS disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

Duration: Up to 17 cycles (approximately 1 year)

15 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety of a new antibody treatment called mosunetuzumab for individuals with aggressive B-cell lymphomas, a type of blood cancer. The treatment follows an autologous stem cell transplant, where patients receive their own stem cells to aid in cancer treatment. Mosunetuzumab helps immune cells target and destroy cancer cells. Individuals who have undergone a stem cell transplant and have certain types of B-cell lymphoma may be suitable candidates for this trial. As a Phase 1 trial, the research aims to understand how mosunetuzumab functions in people, offering participants the opportunity to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot take certain immunosuppressive medications like prednisone over 20 mg within 2 weeks before starting the study. It's best to discuss your specific medications with the study team.

Is there any evidence suggesting that mosunetuzumab is likely to be safe for humans?

Research shows that mosunetuzumab is generally well-tolerated by patients with B-cell non-Hodgkin lymphoma, including aggressive types. Studies have found that mosunetuzumab can lead to lasting improvements in patients whose disease has returned. An important study with over three years of follow-up found mosunetuzumab to be safe. Most side effects were manageable, with only a few serious ones reported. This suggests that mosunetuzumab might be a safe option for patients, although more research is ongoing. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Mosunetuzumab is unique because it offers a new approach for treating aggressive B-cell lymphoma by engaging the body's immune system in a novel way. Unlike standard treatments such as chemotherapy or monoclonal antibodies like rituximab, mosunetuzumab is a bispecific antibody that simultaneously binds to CD20 on B-cells and CD3 on T-cells, effectively redirecting the body's T-cells to attack and destroy cancerous B-cells. Researchers are excited because this targeted mechanism could potentially lead to fewer side effects and more precise treatment, providing hope for better outcomes in patients who have limited options with existing therapies.

What evidence suggests that mosunetuzumab might be an effective treatment for aggressive B-cell lymphoma?

Studies have shown that mosunetuzumab can be effective for aggressive B-cell lymphomas, sometimes causing the cancer to shrink or disappear completely. Among patients who experienced a relapse and received mosunetuzumab again, 83.3% responded well. Additionally, the median progression-free survival, the time during which the cancer did not worsen, was about 24 months. In this trial, participants will receive mosunetuzumab in a step-up dosing schedule. These findings suggest that mosunetuzumab could be a promising treatment option for this type of lymphoma. ^{1 2 6 7 8}

Who Is on the Research Team?

Armin Ghobadi, M.D.

Principal Investigator

Washington University School of Medicine

Are You a Good Fit for This Trial?

Adults with aggressive B cell lymphomas who are planning to undergo autologous stem cell transplant. They must have adequate organ function, no recent major infections or vaccinations, and not be pregnant. Men and women must agree to use effective contraception during the study and for 3 months after the last dose of mosunetuzumab.

Inclusion Criteria

My blood counts meet the required levels without recent medical help.

I have been diagnosed with a specific type of aggressive lymphoma.

My lymphoma has spread to my bone marrow, but I meet specific health criteria.

Exclusion Criteria

I don't have any other cancer that could interfere with this study.

I have had progressive multifocal leukoencephalopathy in the past.

I do not have any major health issues that could interfere with the study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Mosunetuzumab is administered in a step-up dosing schedule beginning on Day 49 after autoSCT, with cycles every 21 days

Up to 17 cycles (approximately 1 year)

Visits on C1D1, C1D8, C1D15, and Day 1 of all subsequent cycles

Follow-up

Participants are monitored for safety and effectiveness after treatment, including PET-CT restaging around Day 100 post-autoSCT

30 days after last dose of mosunetuzumab

Long-term follow-up

Overall survival and progression-free survival are assessed at 2 years post-autoSCT

2 years and 7 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Mosunetuzumab

Trial Overview

The trial is testing mosunetuzumab as a consolidation therapy post-autologous stem cell transplant in patients with relapsed or refractory aggressive B cell lymphomas. Mosunetuzumab is an engineered antibody designed to direct T cells to kill cancerous B cells.

How Is the Trial Designed?

Group I: Consolidation Mosunetuzumab Experimental Treatment 1 Intervention

Mosunetuzumab will be given in a step-up dosing schedule beginning on Day 49 after autoSCT on C1D1, C1D8, C1D15, and then Day 1 of all cycles thereafter (each cycle is 21 days). Patients will undergo PET-CT restaging on Day 100 after autoSCT. Those in complete response (CR) will continue mosunetuzumab from Cycle 3 Day 1 through Cycle 8 Day 1 administered at 30 mg IV. Patients not in CR at Day 100 PET-CT will discontinue study treatment.

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

Genentech, Inc.

Industry Sponsor

Trials

1,578

Recruited

569,000+

Ashley Magargee

Genentech, Inc.

Chief Executive Officer since 2024

MBA from Harvard University, BA from Princeton University

Levi Garraway

Genentech, Inc.

Chief Medical Officer since 2021

MD, PhD

Published Research Related to This Trial

In a phase 1b/2 trial involving 120 patients with relapsed/refractory aggressive large B cell lymphoma, the combination of mosunetuzumab and polatuzumab vedotin achieved a high overall response rate of 59.2% and a complete response rate of 45.9%, indicating strong efficacy as a second-line therapy.

The treatment demonstrated a favorable safety profile, with the most common serious side effects being neutropenia (25%) and fatigue (6.7%), and only 16.7% of patients experiencing any-grade cytokine release syndrome.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. Budde, LE., Olszewski, AJ., Assouline, S., et al.[2023]

Mosunetuzumab, the first bispecific antibody approved for lymphoma, shows significant efficacy in treating relapsed or refractory follicular lymphoma, with an overall response rate of 80% and a complete response rate of 60%.

The approval of mosunetuzumab was based on a phase 2 trial involving patients who had undergone at least two prior lines of systemic therapy, highlighting its potential as a new treatment option for challenging cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. Cao, Y., Marcucci, EC., Budde, LE.[2023]

Mosunetuzumab, a bispecific antibody targeting CD20 and CD3, has received conditional approval in the EU for treating adults with relapsed or refractory follicular lymphoma after at least two prior therapies.

This approval marks a significant milestone in the development of mosunetuzumab, highlighting its potential as a new treatment option for patients with difficult-to-treat lymphoma.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab: First Approval. Kang, C.[2022]

In a phase 2 study involving 40 patients with untreated diffuse large B-cell lymphoma (DLBCL), the combination of mosunetuzumab and CHOP chemotherapy showed high efficacy, with objective and complete response rates of 87.5% and 85.0%, respectively.

The safety profile of mosunetuzumab was manageable, with most adverse events being mild (grade 1 or 2), and only 2.5% of patients experiencing severe neurological side effects, indicating that this treatment could be a promising option for patients with DLBCL.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Olszewski, AJ., Phillips, TJ., Hoffmann, MS., et al.[2023]

Mosunetuzumab, a T-cell-dependent bispecific antibody, is the first approved treatment for relapsed and refractory follicular lymphoma (FL), showing high efficacy and manageable side effects.

The review highlights the evolving treatment landscape for FL, emphasizing the potential of T-cell-redirecting therapies to improve outcomes for patients who have not responded to standard therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. Matarasso, S., Assouline, S.[2023]

In a Phase I study involving 23 Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma, mosunetuzumab was found to be well tolerated, with no deaths reported and manageable side effects, primarily neutropenia and cytokine release syndrome.

The treatment showed promising antitumor activity, with 2 patients achieving complete responses and 11 achieving partial responses, indicating its potential efficacy in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Munakata, W., Izutsu, K., Mishima, Y., et al.[2023]

In a first-in-human trial involving 230 patients with relapsed or refractory B-cell non-Hodgkin lymphomas, mosunetuzumab demonstrated a manageable safety profile with common side effects like neutropenia and cytokine release syndrome, mostly low-grade and occurring primarily in the first treatment cycle.

The treatment showed promising efficacy, with overall response rates of 34.9% for aggressive and 66.2% for indolent B-NHL, and complete response rates of 19.4% and 48.5%, respectively, indicating that mosunetuzumab can induce durable responses in these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Budde, LE., Assouline, S., Sehn, LH., et al.[2023]

In a phase 2 study involving 90 patients with relapsed or refractory follicular lymphoma, mosunetuzumab achieved a complete response rate of 60%, significantly higher than the historical control rate of 14% with copanlisib, demonstrating its efficacy in this patient population.

The treatment was well tolerated, with the most common side effect being cytokine release syndrome, primarily mild to moderate in severity, and no treatment-related fatalities, indicating a favorable safety profile for outpatient administration.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Budde, LE., Sehn, LH., Matasar, M., et al.[2022]

Citations

1.

ashpublications.org

ashpublications.org/blood/article/145/7/708/525779/Long-term-3-year-follow-up-of-mosunetuzumab-in

Long-term 3-year follow-up of mosunetuzumab in relapsed or ...

Median progression-free survival was 24.0 months (95% CI, 12.0 to NE). Median time to CD19+ B-cell recovery was 18.4 months (95% CI, 12.8-25.0) ...

2.

ascopubs.org

ascopubs.org/doi/10.1200/JCO.23.02329

Durable Responses With Mosunetuzumab in Relapsed ...

Among 12 complete responders who progressed postmosunetuzumab treatment and were retreated with mosunetuzumab, 83.3% had an objective response ...

3.

roche.com

roche.com/media/releases/med-cor-2024-12-10

New and updated data for Roche's fixed-duration Columvi ...

Both studies also showed restoration of B-cell levels, starting from 12-18 months following Columvi treatment and after a median of 19 months ...

4.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06828991

NCT06828991 | A Study to Evaluate the Impact of ...

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA ...

5.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38547425/

Extended Follow-Up of a Phase I/II Study

Across dose levels, 65.7% of patients with iNHL and 36.4% with aNHL achieved a complete or partial response to mosunetuzumab. Median duration of ...

6.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/38072960/

Mosunetuzumab with polatuzumab vedotin in relapsed or ...

These data demonstrate that mosunetuzumab plus polatuzumab vedotin has a favorable safety profile with highly durable responses suitable as ...

7.

roche.com

roche.com/media/releases/med-cor-2025-06-20

Roche's Lunsumio and Polivy combination significantly ...

The Lunsumio and Polivy combination demonstrated a 59% reduction in risk of disease progression or death compared to R-GemOx.

8.

nature.com

nature.com/articles/s41591-023-02726-5

Mosunetuzumab with polatuzumab vedotin in relapsed or ...

Mosunetuzumab plus polatuzumab vedotin has a favorable safety profile with highly durable responses suitable as second-line therapy in transplant-ineligible ...